Venclexta™

Venclexta (US), Venclyxto (EU), (ABT-199) is a selective small molecule Bcl-2 inhibitor being investigated for the treatment of multiple cancers.

Type of Molecule

Small Molecule

Target

Bcl-2

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Acute Myeloid Leukemia (AML) US, EU
Phase 3
Chronic Lymphocytic Leukemia (CLL) with 17p deletion US, EU
Approved
Chronic Lymphocytic Leukemia (CLL) - first line US, EU
Phase 3
Chronic Lymphocytic Leukemia (CLL)- relapsed refractory US, EU
Myelodysplatic Syndrome (MDS) US, EU
Phase 2
Multiple Myeloma (MM) n/a
Phase 3
Follicular Lymphoma (FL) US, EU
Phase 2
Diffuse Large B-cell Lymphoma (DLBCL) US, EU
Phase 2